US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArriVent BioPharma

19.53

+0.91004.89%

Post-market: 19.530.00000.00%19:23 EDT

Volume:274.80K

Turnover:5.31M

Market Cap:792.31M

PE:-4.86

High:19.86

Open:18.74

Low:18.47

Close:18.62

52wk High:36.37

52wk Low:15.47

Shares:40.57M

Float Shares:18.29M

Volume Ratio:0.58

T/O Rate:1.50%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0162

EPS(LYR):-2.5577

ROE:-50.06%

ROA:-23.41%

PB:3.17

PE(LYR):-7.64

Loading ...

Overview Company News Filings

Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Stock Track | ArriVent BioPharma Plunges 5.12% Amid Conflicting Analyst Reports

Positive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic Development

ArriVent BioPharma Q2 EPS $(0.90) Misses $(0.72) Estimate

ArriVent Posts Wider Loss in Fiscal Q2

ArriVent Biopharma Inc. Reports Q2 2025 Results: Net Loss Increases to $95.8M, Driven by Higher R&D Expenses

Arrivent Biopharma Inc: Q2 EPS $-0.90

THOMSON REUTERS

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Arrivent Biopharma Inc expected to post a loss of 70 cents a share - Earnings Preview

ArriVent BioPharma Positioned for Success: Buy Rating on Strong Phase 3 Prospects and Financial Health

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial

ArriVent BioPharma Announces Phase 3 Trial Data Release

ArriVent BioPharma Announces Completion of Enrollment for FURVENT Phase 3 Study, Topline Results Expected Early 2026

ArriVent BioPharma, Inc.: Promising Developments and Strategic Advancements Drive Buy Rating

ArriVent BioPharma Price Target Announced at $33.00/Share by Goldman Sachs

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Goldman Sachs

ArriVent BioPharma Announces $75 Million Public Offering

ArriVent Biopharma Files Prospectus for $75 Million Public Offering of Common Stock and Pre-Funded Warrants

BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial

BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, Greenbrier

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AVBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":19.53,"timestamp":1755288000000,"preClose":18.62,"halted":0,"volume":274802,"hourTrading":{"tag":"盘后","latestPrice":19.53,"preClose":19.53,"latestTime":"19:23 EDT","volume":2349,"amount":45876.54,"timestamp":1755300211489},"delay":0,"floatShares":18293400,"shares":40568944,"eps":-4.016159,"marketStatus":"Market Closed","change":0.91,"latestTime":"08-15 16:00:00 EDT","open":18.74,"high":19.855,"low":18.4684,"amount":5305962.20462,"amplitude":0.074468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.016159,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1755504000000},"marketStatusCode":7,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":18.62,"preHourTrading":{"tag":"盘前","latestPrice":18.62,"preClose":18.62,"latestTime":"08:45 EDT","volume":25850,"amount":481327,"timestamp":1755261950467},"postHourTrading":{"tag":"盘后","latestPrice":19.53,"preClose":19.53,"latestTime":"19:23 EDT","volume":2349,"amount":45876.54,"timestamp":1755300211489},"volumeRatio":0.5815462898282058,"impliedVol":0.6794,"impliedVolPercentile":0.8427},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":18293400,"roa":"-23.41%","roe":"-50.06%","lyrEps":-2.557665,"volumeRatio":0.5815462898282058,"shares":40568944,"dividePrice":0,"high":19.855,"amplitude":0.074468,"preClose":18.62,"low":18.4684,"week52Low":15.47,"pbRate":"3.17","week52High":36.37,"institutionHeld":0,"latestPrice":19.53,"eps":-4.016159,"divideRate":0,"volume":274802,"delay":0,"ttmEps":-4.016159,"open":18.74,"prevYearClose":26.64,"prevWeekClose":17.99,"prevMonthClose":19.51,"prevQuarterClose":21.77,"fiveDayClose":17.99,"twentyDayClose":22.05,"sixtyDayClose":20.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9},{"market":"US","date":"2025-05-12","symbol":"AVBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-1.9},{"market":"US","date":"2025-03-03","symbol":"AVBP","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2024-11-14","symbol":"AVBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1753502400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2025-08-15","current":-5.522288,"percent":0.954178,"low":-15.980041,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"high":-4.80343,"avg":-9.536289,"sd":2.432263,"marketCap":755393737},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737}],"updateTime":1755422879484},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559529604","title":"Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559529604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559529604?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:59","pubTimestamp":1755086393,"startTime":"0","endTime":"0","summary":"Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings SummaryArrivent Biopharma Inc AVBP.OQ reported a quarterly adjusted loss of 90 cents per share for the quarter ended Jun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nL8N3U50RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"1189048375","title":"Stock Track | ArriVent BioPharma Plunges 5.12% Amid Conflicting Analyst Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=1189048375","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189048375?lang=en_us&edition=fundamental","pubTime":"2025-08-12 22:37","pubTimestamp":1755009422,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) shares plummeted 5.12% in Tuesday's trading session, as investors grappled with conflicting analyst reports. The significant drop comes as Wall Street analysts provided...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"2558698390","title":"Positive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2558698390","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558698390?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:15","pubTimestamp":1754943315,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on ArriVent BioPharma, Inc. and decreased the price target to $37.00 from $38.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-growth-trajectory-and-buy-rating-for-arrivent-biopharma-inc-driven-by-promising-clinical-data-and-strategic-development-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-growth-trajectory-and-buy-rating-for-arrivent-biopharma-inc-driven-by-promising-clinical-data-and-strategic-development-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2558650624","title":"ArriVent BioPharma Q2 EPS $(0.90) Misses $(0.72) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558650624","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558650624?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:12","pubTimestamp":1754914348,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.72) by 25.52 percent. This is a 38.46 percent decrease over losses of $(0.65) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47028207/arrivent-biopharma-q2-eps-0-90-misses-0-72-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2558685526","title":"ArriVent Posts Wider Loss in Fiscal Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2558685526","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558685526?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:11","pubTimestamp":1754914260,"startTime":"0","endTime":"0","summary":"Net loss per share  was $ for Q2 2025, exceeding the consensus estimate of $.No revenue was recorded for the period, in line with the company’s pre-commercial, clinical-stage focus.Cash and short-term investments increased to $254.5 million as of Q2 2025, bolstered by a July public offering and providing an operational runway into mid-2027.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2025/08/11/arrivent-posts-wider-loss-in-fiscal-q2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2558525650","title":"ArriVent Biopharma Inc. Reports Q2 2025 Results: Net Loss Increases to $95.8M, Driven by Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2558525650","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558525650?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913643,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on August 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL5t7dFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","IE00BGHQF748.EUR","BK1161","LU2210149790.SGD","LU0314104364.USD","BK4588","BK4585","BK4112","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","AVBP","LU2095319765.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2558951650","title":"Arrivent Biopharma Inc: Q2 EPS $-0.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2558951650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558951650?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUA9DD633:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2558573650","title":"ArriVent BioPharma Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558573650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558573650?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913600,"startTime":"0","endTime":"0","summary":"Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130840/0/en/ArriVent-BioPharma-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","PACC","ADC","BK4231","AVBP","BK4139"],"gpt_icon":0},{"id":"2558541176","title":"Arrivent Biopharma Inc  expected to post a loss of 70 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558541176","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558541176?lang=en_us&edition=fundamental","pubTime":"2025-08-11 19:03","pubTimestamp":1754910188,"startTime":"0","endTime":"0","summary":"Arrivent Biopharma Inc  expected to post a loss of70cents a share - Earnings Preview Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to  show no change in quarterly revenue when it reports  results ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nL8N3U30HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2558840816","title":"ArriVent BioPharma Positioned for Success: Buy Rating on Strong Phase 3 Prospects and Financial Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2558840816","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558840816?lang=en_us&edition=fundamental","pubTime":"2025-08-11 06:15","pubTimestamp":1754864111,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy from JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. and keeping the price target at $45.00. Soumit Roy has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-positioned-for-success-buy-rating-on-strong-phase-3-prospects-and-financial-health-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-positioned-for-success-buy-rating-on-strong-phase-3-prospects-and-financial-health-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2553546562","title":"ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2553546562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553546562?lang=en_us&edition=fundamental","pubTime":"2025-07-22 22:25","pubTimestamp":1753194319,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kalpit Patel from B.Riley Financial maintained a Buy rating on ArriVent BioPharma, Inc., with a price target of $37...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/arrivent-biopharma-inc-avbp-receives-a-buy-from-b-riley-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/arrivent-biopharma-inc-avbp-receives-a-buy-from-b-riley-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2553847256","title":"ArriVent BioPharma Announces Phase 3 Trial Data Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2553847256","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553847256?lang=en_us&edition=fundamental","pubTime":"2025-07-21 20:49","pubTimestamp":1753102196,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) just unveiled an update. On July 21, 2025, ArriVent BioPharma announced the projected release of topline data ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-announces-phase-3-trial-data-release?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-announces-phase-3-trial-data-release?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2553471499","title":"ArriVent BioPharma Announces Completion of Enrollment for FURVENT Phase 3 Study, Topline Results Expected Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2553471499","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553471499?lang=en_us&edition=fundamental","pubTime":"2025-07-21 20:09","pubTimestamp":1753099767,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma Inc., a clinical-stage company focused on the global development of biopharmaceutical therapeutics, has announced that topline data from the FURVENT Phase 3 study of firmonertinib monotherapy in first-line EGFR exon20 insertion mutant non-small cell lung cancer  is projected to be available in early 2026. The study, which completed enrollment in the first quarter of 2025, aims to assess progression free survival  by blinded independent central review according to RECIST 1.1 criteria. Firmonertinib has previously received FDA Breakthrough Therapy Designation for this patient population, highlighting the potential significance of the upcoming data. The results of the FURVENT study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDLcf3pWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2552384488","title":"ArriVent BioPharma, Inc.: Promising Developments and Strategic Advancements Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2552384488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552384488?lang=en_us&edition=fundamental","pubTime":"2025-07-17 17:57","pubTimestamp":1752746221,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz has maintained their bullish stance on AVBP stock, giving a Buy rating on July 10. Yigal Nochomovitz has given his B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-promising-developments-and-strategic-advancements-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-promising-developments-and-strategic-advancements-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2550678415","title":"ArriVent BioPharma Price Target Announced at $33.00/Share by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2550678415","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550678415?lang=en_us&edition=fundamental","pubTime":"2025-07-11 02:24","pubTimestamp":1752171840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 10, 2025 14:24 ET (18:24 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2550160526","title":"ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2550160526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550160526?lang=en_us&edition=fundamental","pubTime":"2025-07-10 15:35","pubTimestamp":1752132904,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Corinne Johnson initiated coverage with a Buy rating on ArriVent BioPharma, Inc. today and set a price target of $33.00. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/arrivent-biopharma-inc-avbp-receives-a-buy-from-goldman-sachs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/arrivent-biopharma-inc-avbp-receives-a-buy-from-goldman-sachs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0251131958.USD","IE0002270589.USD","LU2750360997.AUD","BK4550","IE0004086264.USD","IE00BSNM7G36.USD","IE0034235188.USD","LU2237443895.HKD","LU0061475181.USD","BK4127","LU2237443622.USD","LU2237438978.USD","LU2237443978.SGD","IE00B19Z3581.USD","LU2237443382.USD","LU1868837136.USD","BK4533","AVBP","LU0096364046.USD","LU1791807156.HKD","LU2471134879.HKD","LU1868836757.USD","IE00B19Z3B42.SGD","LU1668664300.SGD","LU2237443549.SGD","LU1868837300.USD","LU2471134952.CNY","BK4585","BK4139","BK4552","LU1894683348.USD","LU1868836591.USD","IE00BFXG1179.USD","BK4588","LU2471134523.USD","BK4504","LU0048573561.USD","LU1894683264.USD","LU2471134796.USD","IE0004091025.USD","LU0742534661.SGD","LU0251142724.SGD","LU1868836914.USD","LU0106831901.USD","LU2237443465.HKD","LU2750360641.GBP","BK4516"],"gpt_icon":0},{"id":"2548866843","title":"ArriVent BioPharma Announces $75 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2548866843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548866843?lang=en_us&edition=fundamental","pubTime":"2025-07-03 05:30","pubTimestamp":1751491846,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has shared an update. On July 1, 2025, ArriVent BioPharma, Inc. announced the pricing of an underwritten publi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-announces-75-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-announces-75-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2548484858","title":"ArriVent Biopharma Files Prospectus for $75 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2548484858","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548484858?lang=en_us&edition=fundamental","pubTime":"2025-07-03 05:01","pubTimestamp":1751490073,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering of common stock and pre-funded warrants. The company has filed an automatic shelf registration statement on Form S-3ASR with the SEC, which became effective upon filing on February 3, 2025. The offering includes 2,482,692 shares of common stock priced at $19.50 each and pre-funded warrants for an additional 1,363,469 shares. The proceeds are intended to support the company's pipeline programs and general corporate purposes. The offering, expected to close around July 3, 2025, is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, among others.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL3VqdP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","IE00BFXG1179.USD","LU0477156953.USD","LU1868837300.USD","LU0072461881.USD","LU2236285917.USD","AVBP","LU1201861249.SGD","LU1894683348.USD","LU1894683264.USD","BK4534","LU2125154935.USD","LU1868836591.USD","LU2237443465.HKD","LU0648001328.SGD","LU2237443382.USD","LU2462157665.USD","LU2237443549.SGD","LU1668664300.SGD","LU1791807156.HKD","BK4552","BK4559","LU0742534661.SGD","BK4207","LU0098860793.USD","LU0170899867.USD","LU0162691827.USD","BK4566","LU2456880835.USD","LU2237443895.HKD","BK4139","BK4550","LU0310800965.SGD","IE0004091025.USD","BK4127","LU1366192091.USD","LU0096364046.USD","LU1868837136.USD","LU0048573561.USD","LU0106831901.USD","LU2360032135.SGD","LU1267930227.SGD","IE0004086264.USD","LU0320765646.SGD","BK4533","IE0002270589.USD","LU1868836757.USD","LU0251142724.SGD","LU2417539215.USD","LU0130517989.USD"],"gpt_icon":0},{"id":"2548141158","title":"BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2548141158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548141158?lang=en_us&edition=fundamental","pubTime":"2025-07-03 02:00","pubTimestamp":1751479228,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos FinancialEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL6N3SZ0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANF","VFC","RIVN","DNTH","PRMB","CVX","ZVRA","APA","EQT","AVBP","AX","CNC","FSLR","JBL","KBR","REGN","VRNT","OMDA","STZ","BMRC","CAVA","ELV","SCCO","GEV","ABEO","MO","GBX","ALV","NUE","DFDV","SPOT","CARG","FCX","OGN","STLD","UAA","CVNA","XOM","ROST","ABM","ISTR"],"gpt_icon":1},{"id":"2548897651","title":"BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, Greenbrier","url":"https://stock-news.laohu8.com/highlight/detail?id=2548897651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548897651?lang=en_us&edition=fundamental","pubTime":"2025-07-02 21:10","pubTimestamp":1751461853,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, GreenbrierEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL6N3SZ0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELV","CVNA","LU1551013425.SGD","CNC","LU2213496289.HKD","DFDV","LU0823434740.USD","IE00BQXX3D17.EUR","LU1267930227.SGD","LU1084165304.USD","LU0738911758.USD","SPOT","LU2125154935.USD","LU2324357040.USD","MO","BK4507","ABEO","LU2290526834.HKD","OGN","BHP.AU","CVX","GBX","LU0612318385.USD","JBL","CAVA","SCCO","RIO.AU","AVBP","STZ","XOM","LU2430703251.USD","LU0122376428.USD","APA","LU2028103732.USD","FCX","LU2746668461.USD","ROST","RIO.UK","OMDA","LU0149725797.USD","ALV","LU1883866441.USD","ZVRA","EQT","LU2108987350.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}]}}